An interventional study of Case-finding for Neurocognitive Disorders in Dementia and Mild Cognitive Impairment, sponsored by IRCCS National Neurological Institute "C. Mondino" Foundation. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.
Sponsored by IRCCS National Neurological Institute "C. Mondino" Foundation · Not applicable, Interventional, and Diagnostic
Dementia is a global public health challenge with a heavy caregiving burden, impacting families, communities, and healthcare systems. It is a priority in healthcare planning, with focus on early diagnosis and ongoing support. This research project addresses the global public health challenge posed by dementia, focusing on early detection and comprehensive care. The research evaluates the clinical, social, and healthcare impact of two dementia-related projects in Italy:
The primary goal of this study is to assess the effectiveness of case-finding strategies promoted by the "Ricor-Dare" project for the early detection of cognitive decline. Researchers will compare three different settings in which case-finding will be conducted: at the general practitioners' offices, at the Dementia Operations Center, and at Open Days for the general population. The aim is to measure how many individuals in these three settings are diagnosed with Mild Cognitive Impairment (MCI) or dementia, compared to those identified as potential cases through cognitive testing.
The secondary goal of the study is to assess the social, care, and prevention impact of the activities offered within the two projects. This includes evaluating the experiences of patients and families who access the new CCDD in the province of Pavia, the impact of care pathways on caregivers, and comparing the effectiveness of the new CCDD with existing ones in the region of Lombardia. The study will also assess the role of the "Ricor-Dare" project in addressing the needs of patients, caregivers, and professionals, as well as the effectiveness of awareness-raising and training activities on dementia. Overall, the study aims to provide valuable insights into improving care for people with dementia and supporting their families and caregivers.
Dementia is currently one of the most urgent challenges that global public health must address, with a significant caregiving burden that deeply impacts families, communities, and healthcare systems. It is a key priority in healthcare and social care planning worldwide, with growing emphasis on early diagnosis and appropriate support throughout the course of the disease. According to the World Health Organization, more than 55 million people globally have been diagnosed with dementia, and this number is expected to rise to 139 million by 2050. In Italy, approximately one million people are affected by dementia, and around 900,000 have MCI, with more than three million people directly or indirectly involved in caregiving. However, in high-income countries, the proportion of diagnosed cases remains relatively low, with estimates suggesting that only 20-50% of documented cases are diagnosed in primary care settings. The province of Pavia has 539,239 inhabitants, with an estimated 11,300 individuals diagnosed with dementia and 9,000 with MCI. Consistent with international literature, the ratio of observed to expected cases of dementia and MCI suggests a significant underestimation. Timely diagnosis of the disease or risk of disease enables the person and their caregivers to make informed choices, plan for the future, and gain access to treatments that can help manage symptoms. Centers for Cognitive Disorders and Dementia (CCDD) are healthcare services that play a critical role in the management of dementia and cognitive disorders. Scientific evidence shows that timely access to a specialized cognitive assessment and diagnostic service can lead to better outcomes for individuals with cognitive decline and their families, and be cost-effective for the healthcare system. An accurate and timely diagnosis, support for individuals with dementia and their families, along with early intervention by a multidisciplinary team of healthcare professionals, can have a positive impact on maintaining functional abilities and delaying cognitive decline and institutionalization.
The overall goal of this study is to assess the social and health impact of various services and actions aimed at individuals with cognitive decline within two projects initiated in Italy, specifically in in the Pavia area located in northern Italy: the "Ricor-Dare: integrated territorial network for dementia" project and the opening of a new Cognitive Disorders and Dementia Center (CCDD) Lomellina by Fondazione Mondino in the city of Vigevano. Specifically, the primary goal of this study is to measure the effects of case-finding strategies for the timely detection of dementia in its prodromal or early stages across three different settings. The secondary aim of this study is to evaluate and monitor the social and care effects of the activities offered within the two projects, aimed at patients, caregivers, healthcare professionals, and the community, through a series of indicators reflecting social and health care. This objective will allow for the evaluation, through a set of indicators, of the impact of these complex social and health care, and social actions both on patients identified through case-finding activities and on patients attending the new CCDD Lomellina in the province of Pavia.
For the primary goal of this study, the investigators will evaluate the impact of different case-finding strategies in identifying patients with MCI or dementia. These strategies will be implemented across three different settings:
For the secondary goal of the study, the investigators will assess the experiences of patients and families who access the new CCDD in the province of Pavia, the impact of care pathways on caregivers, and comparing the effectiveness of the new CCDD with existing ones in the region of Lombardia. Below a detailed description of the six secondary outcomes are presented:
2,372 studies on the registry are indexed under Dementia; 574 are open to participants now.
This study's planned enrollment of 490 is above the median of 90 across 1,758 interventional studies indexed under Dementia.
Browse Dementia studies →IRCCS National Neurological Institute "C. Mondino" Foundation is the lead sponsor of 57 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
For the Primary Outcome the inclusion criteria are:
For the Primary Outcome the exclusion criteria are:
For the secondary outcome the inclusion criteria are:
Patient:
Caregiver:
Healthcare professionals:
Fo the Secondary Outcome the exclusion criteria are:
Patient:
Caregiver:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Case-finding for Neurocognitive Disorders
The intervention targets individuals reporting cognitive concerns without a prior diagnosis of MCI or dementia, with participants accessing three different settings for evaluation. The first setting involves General Practitioner (GP) offices, where GPs, trained in dementia risk factors and cognitive assessment tools (such as GPcog), will identify at-risk patients and refer them for further evaluation at a Center for Cognitive Disorders and Dementia (CCDD). The second setting is the Dementia Operations Center (COD) Information Desk, a public service where neuropsychologists assess citizens who independently report cognitive disturbances. The third setting includes Open Days, public events aimed at detecting early signs of cognitive decline, where neuropsychologists will assess participants using the Addenbrooke's Cognitive Examination-III (ACE-III) and the LIBRA Index. Individuals identified as at-risk in any of the three settings will be referred for further evaluation at a CCDD.
Effects of the case-finding strategy for the early detection of dementia in its prodromal or initial stages.
The number of individuals, from the three case-finding settings, diagnosed at the CCDD with Mild Cognitive Impairment (MCI) or dementia within 26 months following assessment at case-finding compared to the total number of people identified as positive cases through GPcog and/or ACE-III and assessed within the three different case-finding settings.
Time frame: Up to 26 months
The impact of the new CCDD on clinical care in an area that previously lacked such services.
Number of patients managed at the new CDCD during the study period, all of whom underwent a baseline neurological examination, a comprehensive neuropsychological assessment, and a follow-up neurological evaluation.
Time frame: Up to 26 months
Patient and caregiver satisfaction with accessing the new CCDD.
Number of completed satisfaction questionnaires from both patients and caregivers and their satisfaction regarding waiting times for the first medical appointments, satisfaction with the initial consultation, fulfillment of needs, and quality of services provided. For each item minimum score is 1 and maximum score is 5, where a higher score indicates higher satisfaction.
Time frame: Up to 26 months
The impact of the diagnostic-care pathway for caregivers at CCDD and "Ricor-Dare" project.
Number of caregivers who completed the initial and final assessments and received support interventions. The efficacy of these interventions is assessed by measuring changes in caregiver burden using the validated Zarit Burden Interview. The minimum score is 0 and the maximum score is 88, where a higher score indicates a greater caregiver burden.
Time frame: Up to 26 months
The impact of the "Dementia Operations Center (COD)" pathway of the "Ricor-Dare" project.
Number of requests received and successfully addressed through the Dementia Operations Center (COD) pathway of the 'Ricor-Dare' project.
Time frame: Up to 26 months
The impact of education activities on dementia promoted by the "Ricor-Dare" project.
Number of people reached.
Time frame: Up to 26 months
Effectiveness of training activities for healthcare and social care professionals promoted by the "Ricor-Dare" project.
Number of healthcare and social care professionals participating in the training activities. The efficacy of these training activities is assessed by measuring changes in knowledge by the validated Dementia Knowledge-20 questionnaire (DK-20). The minimum score is 0 and the maximum score is 11, where a higher score indicates a greater knowledge of dementia.
Time frame: Up to 26 months
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS National Neurological Institute "C. Mondino" Foundation